

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

FORM 10-Q

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended September 30, 2012

OR

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number 001-31668

**INTEGRATED BIOPHARMA, INC.**

(Exact name of registrant, as specified in its charter)

**Delaware**

(State or other jurisdiction of  
incorporation or organization)

**22-2407475**

(I.R.S. Employer  
Identification No.)

**225 Long Ave., Hillside, New Jersey**

(Address of principal executive offices)

**07205**

(Zip Code)

**(888) 319-6962**

(Registrant's telephone number, including Area Code)

**Not Applicable**

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company

Indicate by check whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  No

**Applicable only to Corporate Issuers:**

The number of shares outstanding of each of the issuer's class of common stock, as of the latest practicable date:

Class  
Common Stock, \$0.002 par value

Outstanding at November 15, 2012  
21,080,174 Shares

**INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES**

**FORM 10-Q QUARTERLY REPORT  
For the Three Months Ended September 30, 2012  
INDEX**

	<b><u>Page</u></b>	
<b>Part I. Financial Information</b>		
Item 1.	Condensed Consolidated Statements of Operations for the Three Months Ended September 30, 2012 and 2011 (unaudited)	2
	Condensed Consolidated Balance Sheets as of September 30, 2012 and June 30, 2012 (unaudited)	3
	Condensed Consolidated Statements of Cash Flows for the Three Months Ended September 30, 2012 and 2011 (unaudited)	4
	Notes to Condensed Consolidated Statements	5
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	18
Item 4.	Controls and Procedures	19
<b>Part II. Other Information</b>		
Item 1.	Legal Proceedings	20
Item 1A.	Risk Factors	20
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	20
Item 3.	Defaults Upon Senior Securities	20
Item 4.	Mine Safety Disclosure	20
Item 5.	Other Information	20
Item 6.	Exhibits	20
	<b>Other</b>	
Signatures		21

## **Disclosure Regarding Forward-Looking Statements**

Certain statements in this Quarterly Report on Form 10-Q may constitute “forward-looking” statements as defined in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Act of 1934, as amended (the “Exchange Act”), the Private Securities Litigation Reform Act of 1995 (the “PSLRA”) or in releases made by the Securities and Exchange Commission, all as may be amended from time to time. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Integrated BioPharma, Inc. (the “Company”) or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements that are not historical fact are forward-looking statements. Forward-looking statements can be identified by, among other things, the use of forward-looking language, such as the words, “plan”, “believe”, “expect”, “anticipate”, “intend”, “estimate”, “project”, “may”, “will”, “would”, “could”, “should”, “seeks”, or “scheduled to”, or other similar words, or the negative of these terms or other variations of these terms or comparable language, or by discussion of strategy or intentions. These cautionary statements are being made pursuant to the Securities Act, the Exchange Act and the PSLRA with the intention of obtaining the benefits of the “safe harbor” provisions of such laws. The Company cautions investors that any forward-looking statements made by the Company are not guarantees or indicative of future performance. Important assumptions and other important factors that could cause actual results to differ materially from those forward-looking statements with respect to the Company, include, but are not limited to, the risks and uncertainties affecting its businesses described in Items 1 and 1A of the Company’s Annual Report filed on Form 10-K for the year ended June 30, 2012 and in registration statements and other securities filings by the Company. Although the Company believes that its plans, intentions and expectations reflected in or suggested by such forward-looking statements are reasonable, actual results could differ materially from a projection or assumption in any of the forward-looking statements and are subject to change due inherent risks and uncertainties. The forward-looking statements contained in this Quarterly Report on Form 10-Q are made only as of the date hereof and the Company does not have or undertake any obligation to update or revise any forward-looking statements whether as a result of new information, subsequent events or otherwise, unless otherwise required by law.

## ITEM 1. FINANCIAL STATEMENTS

**INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  
*(in thousands, except for share and per share amounts)*  
**(Unaudited)**

	<b>Three months ended</b>	
	September 30,	
	<u>2012</u>	<u>2011</u>
Sales, net	\$ 8,480	\$ 10,876
Cost of sales	<u>6,915</u>	<u>8,123</u>
Gross profit	1,565	2,753
Selling and administrative expenses	<u>1,196</u>	<u>2,143</u>
Operating income	369	610
Other expense, net		
Change in fair value of derivative liabilities	(1,085)	10
Interest expense	(248)	(260)
Net gain (loss) on disposal of property and equipment	<u>(6)</u>	<u>3</u>
Other expense, net	<u>(1,339)</u>	<u>(247)</u>
(Loss) income before income taxes	(970)	363
Income tax expense, net	<u>2</u>	<u>-</u>
Net (loss) income	<u>\$ (972)</u>	<u>\$ 363</u>
Basic and diluted net income (loss) per common share	<u>\$ (0.05)</u>	<u>\$ 0.02</u>
Weighted average common shares outstanding	<u>21,080,174</u>	<u>20,936,813</u>

See accompanying notes to condensed consolidated financial statements.

**INTEGRATED BIOPHARMA, INC.**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
*(in thousands, except for share and per share amounts)*  
**(Unaudited)**

	<u>September 30,</u> 2012	<u>June 30,</u> 2012
<b>Assets</b>		
<b>Current Assets:</b>		
Cash	\$ 216	\$ 145
Accounts receivable, net	2,256	2,035
Inventories	5,451	5,290
Investment in iBio, Inc., restricted	823	823
Other current assets	439	391
<b>Total current assets</b>	<u>9,185</u>	<u>8,684</u>
Intangible assets, net	1,119	1,154
Property and equipment, net	1,359	1,449
Security deposits and other assets	511	590
<b>Total Assets</b>	<u>\$ 12,174</u>	<u>\$ 11,877</u>
<b>Liabilities and Stockholders' Deficiency:</b>		
<b>Current Liabilities:</b>		
Advances under revolving credit facility	\$ 2,955	\$ 2,677
Accounts payable (includes \$76 and \$72 due to related party, respectively)	6,407	6,481
Accrued expenses and other current liabilities	1,594	1,549
Current portion of long term debt	1,540	1,496
<b>Total current liabilities</b>	<u>12,496</u>	<u>12,203</u>
Long term debt	4,563	4,698
Subordinated convertible note, net - CD Financial LLC	4,822	4,796
Derivative liabilities	1,648	563
<b>Total liabilities</b>	<u>23,529</u>	<u>22,260</u>
<b>Commitments and Contingencies</b>		
<b>Stockholders' Deficiency:</b>		
Common Stock, \$0.002 par value; 50,000,000 shares authorized; 21,115,074 and 21,080,174 shares issued and outstanding, respectively	42	42
Additional paid-in capital	44,568	44,568
Accumulated deficit	(55,866)	(54,894)
Less: Treasury stock, at cost, 34,900 shares	(99)	(99)
<b>Total Stockholders' Deficiency</b>	<u>(11,355)</u>	<u>(10,383)</u>
<b>Total Liabilities and Stockholders' Deficiency</b>	<u>\$ 12,174</u>	<u>\$ 11,877</u>

See accompanying notes to condensed consolidated financial statements.

**INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
*(in thousands, except share and per share amounts)*  
**(Unaudited)**

	Three months ended September 30,	
	2012	2011
Cash flows provided by operating activities:		
Net (loss) income	\$ (972)	\$ 363
Adjustments to reconcile net (loss) income to net cash provided by operating activities:		
Depreciation and amortization	107	120
Accretion of financing instruments	57	-
Financing costs for stock issued in connection with Convertible Note Payable	-	4
Change in fair value of derivative liabilities	1,085	(10)
Loss (gain) on sale of fixed assets	6	(2)
Compensation expense for employee stock options	-	5
Changes in assets and liabilities:		
Decrease (increase) in:		
Accounts receivable	(221)	(707)
Inventories	(161)	1,005
Other current assets	(48)	33
Security deposits and other assets	49	(3)
(Decrease) increase in:		
Accounts payable	(73)	(1,975)
Accrued expenses and other liabilities	45	1,384
<b>Net cash (used in) provided by operating activities</b>	<b>(126)</b>	<b>217</b>
Cash flows from investing activities:		
Purchase of property and equipment	(8)	(1)
Proceeds from sale of property and equipment	18	2
<b>Net cash provided by investing activities</b>	<b>10</b>	<b>1</b>
Cash flows from financing activities:		
Advances under revolving credit facility	8,527	-
Repayments under revolving credit facility	(8,250)	-
Payments under term notes	(90)	-
Payments under capital lease obligations	-	(12)
<b>Net provided by (cash used) in financing activities</b>	<b>187</b>	<b>(12)</b>
Net increase in cash	71	206
Cash at beginning of period	145	725
Cash at end of period	<b>\$ 216</b>	<b>\$ 931</b>
Supplemental disclosures of cash flow information:		
Cash paid during the periods for:		
Interest	\$ 126	\$ 263
Income taxes	\$ 3	\$ 3

See accompanying notes to condensed consolidated financial statements.

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
AS OF SEPTEMBER 30, 2012 AND JUNE 30, 2012 AND FOR THE  
THREE MONTHS ENDED SEPTEMBER 30, 2012 AND 2011  
(in thousands, except share and per share amounts)  
(Unaudited)

***Note 1. Principles of Consolidation and Basis of Presentation***

***Basis of Presentation of Interim Financial Statements***

The accompanying condensed consolidated financial statements for the interim periods are unaudited and include the accounts of Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the “Company”). The interim condensed consolidated financial statements have been prepared in conformity with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and therefore do not include information or footnotes necessary for a complete presentation of financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States of America. However, all adjustments (consisting only of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the periods presented have been included. These condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto, together with Management’s Discussion and Analysis of Financial Condition and Results of Operations, contained in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2012 (“Form 10-K”), as filed with the SEC. The June 30, 2012 balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. The results of operations for the three months ended September 30, 2012 are not necessarily indicative of the results for the full fiscal year ending June 30, 2013 or for any other period.

***Nature of Operations***

The Company is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company’s customers are located primarily in the United States, Luxembourg and Canada. The Company was previously known as Integrated Health Technologies, Inc. and, prior to that, as Chem International, Inc. The Company was reincorporated in its current form in Delaware in 1995. The Company continues to do business as Chem International, Inc. with certain of its customers and certain vendors.

The Company’s nutraceutical business includes: InB:Manhattan Drug Company, Inc. (“MDC”), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers; AgroLabs, Inc. (“AgroLabs”), which distributes healthful nutritional products for sale through major mass market, grocery, drug and vitamin retailers, under the following brands: Naturally Noni, Naturally Pomegranate, Pomegranate with ACAI and Resveratrol, Coconut Water, Naturally Aloe, Aloe Pure, Peaceful Sleep, Green Envy, ACAI Extra, ACAI Immune, ACAI Cleanse, and other products which are being introduced into the market (these are referred to as our branded proprietary nutraceutical business and/or products); and The Vitamin Factory (the “Vitamin Factory”), which sells private label MDC products, as well as our AgroLabs products, through the Internet.

The Company also distributes fine natural chemicals through its wholly-owned subsidiary IHT Health Products, Inc. (“IHT”) and is a distributor of certain raw materials for DSM Nutritional Products, Inc.

***Significant Accounting Policies***

There have been no material changes during fiscal year 2013 in the Company’s significant accounting policies to those previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2012.

***Investment in iBio, Inc.- Restricted.*** The Company accounts for its investment in iBio, Inc. (“iBio”) common stock on the cost basis as it retained approximately 6% of its interest in iBio (1,266,706 common shares) (the “iBio Stock”) at the time of the spin-off of this subsidiary in August 2008. The Company reviews its investment

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
AS OF SEPTEMBER 30, 2012 AND JUNE 30, 2012 AND FOR THE  
THREE MONTHS ENDED SEPTEMBER 30, 2012 AND 2011  
*(in thousands, except share and per share amounts)*  
*(Unaudited)*

in iBio for impairment and records a loss when there is deemed to be an impairment of the investment. There was no impairment charge recorded in each of the three month periods ended September 30, 2012 and 2011. The market value of the iBio Stock as of September 30, 2012 was approximately \$1.3 million. Pursuant to the Company's Loan Agreement with PNC Bank, National Association ("PNC"), PNC may sell the iBio Stock when the trading price of the iBio Stock is less than \$0.88 per share for a period of fifteen (15) consecutive trading days on the applicable exchange and utilize all proceeds from such sale to prepay the outstanding principal of the term loan outstanding under the Loan Agreement at such time. (See Note 5. Senior Credit Facility, Subordinated Convertible Note Payable, net - CD Financial, LLC and other Long Term Debt).

**Earnings Per Share.** Basic earnings per common share amounts are based on the weighted average number of common shares outstanding. Diluted earnings per share amounts are based on the weighted average number of common shares outstanding, plus the incremental shares that would have been outstanding upon the assumed exercise of all potentially dilutive stock options, warrants and convertible preferred stock, subject to anti-dilution limitations using the treasury stock method.

Stock options and warrants to purchase or otherwise obtain 2,766,088 shares of common stock were not included in the fully diluted computation for earnings per share as their exercise prices were greater than the market price of the common shares as of September 30, 2012 and stock options to purchase or otherwise obtain 646,250 shares of common stock were not included in the fully diluted computation for earnings per share as they were anti-dilutive as a result of net losses applicable to common shareholders.

Stock options and warrants to purchase or otherwise obtain shares of common stock were not included in the fully diluted computation for earnings per share as their exercise prices were greater than the market price of the common shares as of September 30, 2011.

For the three months ended September 30, 2012 and 2011, common shares issuable upon a conversion of the Original CD Note and the CD Convertible Note, respectively of 8,230,769 and 2,250,000, respectively, were not included in the computation of diluted earnings per share as they were anti-dilutive. (See Note 5. Senior Credit Facility, Subordinated Convertible Note Payable, net - CD Financial, LLC and other Long Term Debt).

**Note 2. Inventories**

Inventories are stated at the lower of cost or market using the first-in, first-out method and consist of the following as of:

	September 30, 2012	June 30, 2012
	<u>          </u>	<u>          </u>
Raw materials	\$ 2,571	\$ 2,502
Work-in-process	1,073	1,344
Finished goods	<u>1,807</u>	<u>1,444</u>
Total	<u>\$ 5,451</u>	<u>\$ 5,290</u>



INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
AS OF SEPTEMBER 30, 2012 AND JUNE 30, 2012 AND FOR THE  
THREE MONTHS ENDED SEPTEMBER 30, 2012 AND 2011  
(in thousands, except share and per share amounts)  
(Unaudited)

**Note 3. Intangible Assets, net**

Intangible assets consist of trade names, license fees, and unpatented technology. The carrying amount of other intangible assets, net is as follows as of:

	September 30, 2012			June 30, 2012		
	Gross Carrying Amount	Accumulated Amortization	Net	Gross Carrying Amount	Accumulated Amortization	Net
Trade names and patents	\$ 1,525	\$ 682	\$ 843	\$ 1,525	\$ 663	\$ 862
Unpatented technology	547	430	117	547	420	127
License agreement	347	188	159	347	182	165
<b>Total</b>	<b>\$ 2,419</b>	<b>\$ 1,300</b>	<b>\$ 1,119</b>	<b>\$ 2,419</b>	<b>\$ 1,265</b>	<b>\$ 1,154</b>

Amortization expense recorded on intangible assets for the three months ended September 30, 2012 and 2011 was \$35 and \$34, respectively. Amortization expense is recorded on the straight-line method over periods ranging from 2 years to 20 years based on contractual or estimated lives and is included in selling and administrative expenses.

The estimated annual amortization expense for intangible assets for the five succeeding fiscal years is as follows:

Year ending June 30,	Amortization Expense
2013, remaining	\$ 102
2014	137
2015	137
2016	104
2017	97
2018	97
Thereafter	445
<b>Total</b>	<b>\$ 1,119</b>

**Note 4. Property and Equipment, net**

Property and equipment, net consists of the following as of:

	September 30, 2012	June 30, 2012
Land and building	\$ 1,250	\$ 1,250
Leasehold improvements	1,132	1,132
Machinery and equipment	4,837	5,017
Transportation equipment	59	59
	7,278	7,458
Less: Accumulated depreciation and amortization	(5,919)	(6,009)
<b>Total</b>	<b>\$ 1,359</b>	<b>\$ 1,449</b>

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
AS OF SEPTEMBER 30, 2012 AND JUNE 30, 2012 AND FOR THE  
THREE MONTHS ENDED SEPTEMBER 30, 2012 AND 2011  
*(in thousands, except share and per share amounts)*  
*(Unaudited)*

Depreciation and amortization expense was \$73 and \$86 for the three months ended September 30, 2012 and 2011, respectively. In the three months ended September 30, 2012, the Company disposed of property and equipment with an original cost of \$188 for net proceeds of \$18. For the three months ended September 30, 2011, the Company disposed of fully depreciated property and equipment with an original cost of \$2 for net proceeds of \$2.

**Note 5. Senior Credit Facility, Subordinated Convertible Note Payable, net - CD Financial, LLC and other Long Term Debt**

As of September 30 and June 30, 2012, the Company had the following debt outstanding:

	Principal Amount		Interest Rate	Maturity Date
	As of September 30, 2012	As of June 30, 2012		
Revolving advances under Senior Credit Facility with PNC Bank, National Association	\$ 2,955	\$ 2,677	3.25%	6/27/2017
Installment Note with PNC Bank	3,638	3,727	3.75%	6/27/2017
Promissory Note with CD Financial, LLC	1,714	1,714	6.00%	7/7/2017
Promissory Note with Vitamin Realty, LLC	686	686	4.00%	7/7/2017
Promissory Note with E. Gerald Kay	27	27	4.00%	7/7/2017
Promissory Note with Acura Financial Services	38	40	1.90%	4/15/2017
Total outstanding debt	9,058	8,871		
Less: Revolving Advances	(2,955)	(2,677)		
Current portion of long term debt	(1,540)	(1,496)		
Long term debt	<u>\$ 4,563</u>	<u>\$ 4,698</u>		
Convertible Note payable - CD Financial, LLC	\$ 5,350	\$ 5,350		
Discount for embedded derivative	(528)	(554)		
Convertible Note payable, net - CD Financial, LLC	<u>\$ 4,822</u>	<u>\$ 4,796</u>		

**SENIOR CREDIT FACILITY**

On June 27, 2012, the Company, MDC, AgroLabs, IHT, IHT Properties Corp. (“IHT Properties”) and Vitamin Factory (collectively, the “Borrowers”) entered into a Revolving Credit, Term Loan and Security Agreement (the “Loan Agreement”) with PNC as agent and lender and the other lenders party thereto.

The Loan Agreement provides for a total of \$11,727 in senior secured financing (the “Senior Credit Facility”) as follows: (i) discretionary advances (“Revolving Advances”) based on eligible accounts receivable and eligible inventory in the maximum amount of \$8,000 (the “Revolving Credit Facility”) and (ii) a term loan in the amount of \$3,727 (the “Term Loan”). The Senior Credit Facility is secured by all assets of the Borrowers, including, without limitation, machinery and equipment, real estate owned by IHT Properties, and the iBio Stock owned by the Company. Revolving Advances bear interest at PNC’s Base Rate or the Eurodollar Rate, at Borrowers’ option, plus 2.75% (3.25% as of September 30 and June 30, 2012). The Term Loan bears interest at PNC’s Base Rate or the Eurodollar Rate, at Borrowers’ option, plus 3.25% (3.75% as of September 30 and June 30, 2012). Upon and after the occurrence of any event of default under the Loan Agreement, and during the continuation thereof,

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
AS OF SEPTEMBER 30, 2012 AND JUNE 30, 2012 AND FOR THE  
THREE MONTHS ENDED SEPTEMBER 30, 2012 AND 2011  
*(in thousands, except share and per share amounts)*  
*(Unaudited)*

interest shall be payable at the interest rate then applicable plus 2%. The Senior Credit Facility matures on June 27, 2017 (the “Senior Maturity Date”).

The principal balance of the Revolving Advances is payable on the Senior Maturity Date, subject to acceleration, based upon a material adverse event clause, as defined, subjective accelerations for borrowing base reserves, as defined or upon the occurrence of any event of default under the Loan Agreement or earlier termination of the Loan Agreement pursuant to the terms thereof. The Term Loan shall be repaid in sixty (60) consecutive monthly installments of principal, the first fifty nine (59) of which shall be in the amount of \$44, commencing on the first business day of August, 2012, and continuing on the first business day of each month thereafter, with a final payment of any unpaid balance of principal and interest payable on the first business day of July, 2017. The foregoing is subject to customary mandatory prepayment provisions and acceleration upon the occurrence of any event of default under the Loan Agreement or earlier termination of the Loan Agreement pursuant to the terms thereof.

The Revolving Advances are subject to the terms and conditions set forth in the Loan Agreement and are made in aggregate amounts at any time equal to the lesser of (x) \$8.0 million or (y) an amount equal to the sum of: (i) up to 85%, subject to the provisions in the Loan Agreement, of eligible accounts receivables (“Receivables Advance Rate”), plus (ii) up to the lesser of (A) 65%, subject to the provisions in the Loan Agreement, of the value of the eligible inventory (“Inventory Advance Rate” and together with the Receivables Advance Rate, collectively, the “Advance Rates”), (B) 85% of the appraised net orderly liquidation value of eligible inventory (as evidenced by the most recent inventory appraisal reasonably satisfactory to PNC in its sole discretion exercised in good faith) and (C) the inventory sublimit in the aggregate at any one time (“Inventory Advance Rate” and together with the Receivables Advance Rate, collectively, the “Advance Rates”), minus (iii) the aggregate Maximum Undrawn Amount of all outstanding Letters of Credit, minus (iv) such reserves as Agent may reasonably deem proper and necessary from time to time.

The Loan Agreement contains customary mandatory prepayment provisions, including, without limitation, (i) the requirement that if the trading price per share of the iBio Stock falls below a certain amount, the Company must sell the iBio Stock and use the proceeds to repay the Term Loan and (ii) the outstanding amount of all loans in an amount equal to fifty percent (50%) of Excess Cash Flow for each fiscal year commencing with the fiscal year ending June 30, 2013, payable upon delivery of the financial statements to PNC referred to in and required by the Loan Agreement for such fiscal year but in any event not later than one hundred twenty (120) days after the end of each such fiscal year, which prepayment amount shall be applied ratably to the outstanding principal installments of the Term Loan in the inverse order of the maturities thereof until the aggregate amount of payments made with regard to the Term Loan pursuant to Loan Agreement equals \$1.0 million. The Loan Agreement also contains customary representations and warranties, covenants and events of default, including, without limitation, (i) a fixed charge coverage ratio maintenance requirement and (ii) an event of default tied to any change of control as defined in the Loan Agreement. As of September 30, 2012, the Company is in compliance with the fixed charge coverage ratio maintenance requirement.

In connection with the Senior Credit Facility, each of E. Gerald Kay, an officer, director and major stockholder of the Company, and Carl DeSantis, a director and major stockholder of the Company (collectively, the “Guarantors”), entered into Continuing Limited Guarantees (collectively, the “Individual Guarantees”) with PNC whereby each Guarantor irrevocably and unconditionally guarantees the full, prompt and unconditional payment, when due, whether by acceleration or otherwise, of any and all obligations of the Borrowers under the Loan Agreement and the other loan documents. The liability of each Guarantor under his respective Individual Guarantee is limited to a maximum of \$1.0 million. The Individual Guarantees will automatically terminate upon the satisfaction of certain conditions set forth in the Loan Agreement.

Also, in connection with the Senior Credit Facility, PNC and CD Financial, LLC (“CD Financial”) entered into the Intercreditor and Subordination Agreement (the “Intercreditor Agreement”), which was acknowledged by the

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
AS OF SEPTEMBER 30, 2012 AND JUNE 30, 2012 AND FOR THE  
THREE MONTHS ENDED SEPTEMBER 30, 2012 AND 2011  
*(in thousands, except share and per share amounts)*  
*(Unaudited)*

Borrowers, pursuant to which, among other things, (a) the lien of CD Financial on assets of the Borrowers is subordinated to the lien of PNC on such assets during the effectiveness of the Senior Credit Facility, and (b) priorities for payment of the debt for the Company and its subsidiaries (as described in this Note 5) are established.

In addition, in connection with the Senior Credit Facility, the following loan documents were executed: (i) the Company has entered into a Stock Pledge Agreement with PNC, pursuant to which the Company pledged to PNC the iBio Stock; (ii) IHT Properties has entered into a Mortgage and Security Agreement with PNC; and (iii) the Borrowers have entered into an Environmental Indemnity Agreement with PNC.

### **CD FINANCIAL, LLC TROUBLED DEBT RESTRUCTURING**

On June 27, 2012, the Company also entered into an Amended and Restated Securities Purchase Agreement (the “CD SPA”) with CD Financial, which amended and restated the Securities Purchase Agreement, dated as of February 21, 2008, between the Company and CD Financial, pursuant to which the Company issued to CD Financial a 9.5% Convertible Senior Secured Note in the original principal amount of \$4,500 (the “Original CD Note”). Pursuant to the CD SPA, the Company issued to CD Financial (i) the Amended and Restated Convertible Promissory Note in the principal amount of \$5,350 (the “CD Convertible Note”) and (ii) the Promissory Note in the principal amount of \$1,714 (the “Liquidity Note”, and collectively with the CD Convertible Note, the “CD Notes”). The CD Notes mature on July 7, 2017. In accordance with the applicable accounting guidance, this transaction was accounted for as a troubled debt restructuring. No gain on debt extinguishment was recognized as the undiscounted cash flows of the restructured debt was greater than the carrying amount of the debt prior to the restructuring.

The CD Notes are secured by all assets of the Borrowers, including, without limitation, machinery and equipment, real estate owned by IHT Properties, and iBio Stock owned by the Company. The CD Notes bear interest at an annual rate of 6% and have a default rate of 10%.

The CD Convertible Note is convertible at the option of CD Financial into common stock of the Company at a conversion price of \$0.65 per share, subject to customary adjustments including conversion price protection provisions.

Pursuant to the terms of the Loan Agreement and the Intercreditor Agreement, during the effectiveness of the Senior Credit Facility, (i) the principal of the CD Convertible Note may not be repaid, (ii) the principal of the Liquidity Note may only be repaid if certain conditions under the Loan Agreement are satisfied, and (iii) interest in respect of the CD Notes may only be paid if certain conditions under the Intercreditor Agreement are satisfied.

The CD SPA contains customary representations and warranties, covenants and events of default, including, without limitation, an event of default tied to any change of control as defined in the CD SPA.

In connection with the CD SPA, the Borrowers entered into an Amended and Restated Security Agreement and Amended and Restated Subsidiary Guaranty.

As of September 30 and June 30, 2012, the related embedded derivative liability with respect to the CD Convertible Note has an estimated fair value of \$1,621 and \$555, respectively.

The Company used the following assumptions to calculate the fair value of the derivative liability using the Black-Scholes option pricing model:

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
AS OF SEPTEMBER 30, 2012 AND JUNE 30, 2012 AND FOR THE  
THREE MONTHS ENDED SEPTEMBER 30, 2012 AND 2011  
*(in thousands, except share and per share amounts)*  
*(Unaudited)*

	September 30, 2012	June 30, 2012	Issuance Date- June 27, 2012
Risk Free Interest Rate	0.62%	0.72%	0.72%
Volatility	136.20%	144.10%	144.10%
Term	4.75 years	5 years	5 years
Dividend Rate	0.00%	0.00%	0.00%
Closing Price of Common Stock	\$ 0.25	\$ 0.09	\$ 0.09

**OTHER LONG TERM DEBT**

On June 27, 2012, MDC and the Company entered into separate promissory notes with (i) Vitamin Realty Associates, LLC (“Vitamin Realty”) , which is 90% owned by the Company’s chairman, president and major stockholder and certain family members, who are also executive officers and directors of the Company, and (ii) E. Gerald Kay, the Company’s Chief Executive Officer, Chairman of the Board, President and a majority shareholder, in the principal amounts of approximately \$686 (the “Vitamin Note”) and \$27 (the “Kay Note”), respectively (collectively the “Related Party Notes”). The principal amount of the Vitamin Note represents the aggregate amount of unpaid, past due rent owing by MDC under the Lease Agreement, dated as of January 10, 1997, between MDC, as lessor, and Vitamin Realty, as landlord, pertaining to the real property located at 225 Long Avenue, Hillside, New Jersey. (See Note 7. Commitments and Contingencies (a) Leases – Related Parties). The Kay Note represents amounts owed to Mr. Kay for unreimbursed business expenses incurred by Mr. Kay in the fiscal year ended June 30, 2008. The Related Party Notes mature on July 7, 2017 and accrue interest at an annual rate of 4% per annum. Interest in respect of the Related Party Notes is payable on the first business day of each calendar month. Pursuant to the terms of the Loan Agreement, during the effectiveness of the Senior Credit Facility, the Related Party Notes may only be repaid or prepaid if certain conditions set forth in the Loan Agreement are satisfied.

On March 31, 2012, the Company entered into an auto loan financing with Acura Financial Services, Inc, in the amount of \$41, which loan is secured by an automobile and matures on April 15, 2017. Interest and principal in the amount of less than \$1 is payable monthly and bears interest at the rate of 1.9%.

**Note 6. Significant Risks and Uncertainties**

**(a) Major Customers.** For the three months ended September 30, 2012, approximately 72% of total net sales were derived from two customers as compared to approximately 80% of total net sales derived from two customers in the three months ended September 30, 2011. Accounts receivable as of September 30, 2012 from these customers represented approximately 64% of total accounts receivable. The loss of either of these customers would have an adverse affect on the Company’s operations. Major customers are those customers who account for more than 10% of net sales.

**(b) Other Business Risks.** Approximately 61% the Company’s employees are covered by a union contract and are employed in its New Jersey facilities. The union contract was renewed in May 2012 and expires in August 2015.

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
AS OF SEPTEMBER 30, 2012 AND JUNE 30, 2012 AND FOR THE  
THREE MONTHS ENDED SEPTEMBER 30, 2012 AND 2011  
(in thousands, except share and per share amounts)  
(Unaudited)

**Note 7. Commitments and Contingencies**

**(a) Leases**

Related Party Leases. Warehouse and office facilities are leased from Vitamin Realty. On January 5, 2012, MDC, a wholly-owned subsidiary of the Company, entered into a second amendment of lease (the “Second Lease Amendment”) with Vitamin Realty for its office and warehouse space in New Jersey increasing its rentable square footage from an aggregate of 74,898 square feet to 76,161 square feet and extending the expiration date to January 31, 2026. This Second Lease Amendment provides for minimum annual rental payments of \$533, plus increases in real estate taxes and building operating expenses. Also on January 5, 2012, AgroLabs entered into a lease agreement with Vitamin Realty for an additional 2,700 square feet of warehouse space in New Jersey, the term of which expires on January 31, 2019. This additional lease provides for minimum lease payments of \$27 with annual increases plus the proportionate share of operating expenses.

Rent expense for the three months ended September 30, 2012 and 2011 on these leases were \$271 and \$184 respectively, and are included in both cost of sales and selling and administrative expenses in the accompanying Condensed Consolidated Statements of Operations. As of September 30, 2012 and June 30, 2012, the Company had an outstanding obligation of \$784 and \$776, respectively, included in accounts payable and long term debt in the accompanying Condensed Consolidated Balance Sheet.

**Other Lease Commitments.** The Company has entered into certain non-cancelable operating lease agreements expiring up through January 31, 2026, related to office and warehouse space, equipment and vehicles.

The minimum rental commitment for long-term non-cancelable leases is as follows:

Year ending June 30,	Lease Commitment	Related Party Lease Commitment	Total
2013, remaining	\$ 39	\$ 422	\$ 461
2014	29	563	592
2015	12	563	575
2016	12	563	575
2017	4	563	567
2018	-	563	563
Thereafter	-	4,060	4,060
<b>Total</b>	<u>\$ 96</u>	<u>\$ 7,297</u>	<u>\$ 7,393</u>

Total rent expense, including real estate taxes and maintenance charges, was approximately \$338 and \$276 for the three months ended September 30, 2012 and 2011, respectively. Rent expense is included in cost of sales and selling and administrative expenses in the accompanying Condensed Consolidated Statements of Operations.

**(b) Legal Proceedings.**

The Company is subject, from time to time, to claims by third parties under various legal theories. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows.

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
AS OF SEPTEMBER 30, 2012 AND JUNE 30, 2012 AND FOR THE  
THREE MONTHS ENDED SEPTEMBER 30, 2012 AND 2011  
*(in thousands, except share and per share amounts)*  
*(Unaudited)*

***(c) Other Claims.***

On May 15, 2012, Cedarburg Pharmaceuticals, Inc. ("Cedarburg") sent the Company a letter (the "Demand Letter") setting forth a demand for indemnification under the Stock Purchase Agreement, dated March 17, 2009 (the "Cedarburg SPA"), by and among Cedarburg, InB: Hauser Pharmaceutical Services, Inc., InB: Paxis Pharmaceuticals, Inc. and the Company. In the Demand Letter, Cedarburg demanded payment by the Company of \$0.6 million in respect of the Company's indemnification obligations under the Cedarburg SPA. In addition, in the Demand Letter, Cedarburg informed the Company that there are also environmental issues pending which may lead to additional costs to Cedarburg which will likely be in excess of \$0.3 million.

On May 30, 2012, the Company sent a letter responding to the Demand Letter and setting forth the Company's position that it has no obligation to indemnify Cedarburg as demanded. On June 18, 2012, Cedarburg responded to the Company's letter and, on July 27, 2012, the Company sent another letter to Cedarburg reiterating its position that the Company has no obligation to indemnify Cedarburg as demanded. As of November 19, 2012, the Company has not received any further communication from Cedarburg with respect to its demand for indemnification as set forth in the Demand Letter. The Company intends to vigorously contest Cedarburg's demand as set forth in the Demand Letter.

***Note 8. Related Party Transactions***

On June 27, 2012, Carl DeSantis, a director and major shareholder of the Company and a member of CD Financial and E. Gerald Kay, the Company's Chief Executive Officer, Chairman of the Board, President and a major shareholder each entered into Limited Guaranty Agreements with PNC in the amount of \$1.0 million each. (See Note 5. Senior Credit Facility, Subordinated Convertible Note Payable, net - CD Financial, LLC and other Long Term Debt).

Neither Mr. DeSantis nor Mr. Kay received any compensation from the Company in connection with these guarantees.

See Note 5. Senior Credit Facility, Subordinated Convertible Note Payable, net - CD Financial, LLC and other Long Term Debt for related party securities transactions.

See Note 7(a). Leases for related party lease transactions.

## **Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION**

Certain statements set forth under this caption constitute “forward-looking statements.” See “Disclosure Regarding Forward-Looking Statements” on page 1 of this Quarterly Report on Form 10-Q for additional factors relating to such statements. The following discussion should also be read in conjunction with the condensed consolidated financial statements of the Company and Notes thereto included herein and the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2012.

The Company is engaged primarily in the manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company’s customers are located primarily in the United States, Luxembourg and Canada.

### ***Business Outlook***

Our future results of operations and the other forward-looking statements contained in this Quarterly Report on Form 10-Q, including this MD&A, involve a number of risks and uncertainties—in particular, the statements regarding our goals and strategies, new product introductions, plans to cultivate new businesses, pending divestitures, future economic conditions, revenue, pricing, gross margin and costs, the tax rate, and potential legal proceedings. We are focusing our efforts to improve operational efficiency and reduce spending that may have an impact on expense levels and gross margin. In addition to the various important factors discussed above, a number of other important factors could cause actual results to differ significantly from our expectations. See the risks described in “Risk Factors” in Part II, Item 1A of this Quarterly Report on Form 10-Q.

Our management team continues to focus on expanding our customer base to decrease our financial reliance on our historical major customers. In the three months ended September 30, 2012, our sales to our major customers decreased to approximately 72% of net sales from approximately 80% of net sales in the three months ended September 30, 2011. We believe that this expansion in our customer base may lead to more sales as each of these new customers should increase the volume of business in the future. Additionally, as our sales volumes continue to grow, our fixed overhead costs will be allocated over more sales and ultimately decrease as a percentage of sales.

In the quarter ended September 30, 2012, our income from operations was approximately \$0.4 million, which results covered our debt service requirements and provided additional cash flows to pay our suppliers in a more timely manner than in the past and improve relationships with them.

### ***Critical Accounting Policies and Estimates***

There have been no changes to our critical accounting policies in the three months ended September 30, 2012. Critical accounting policies and the significant estimates made in accordance with them are regularly discussed by management with our Audit Committee. Those policies are discussed under “Critical Accounting Policies” in our “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Item 7 of our Annual Report on Form 10-K for the year ended June 30, 2012.



## Results of Operations

Our results from operations in the following table, sets forth the income statement data of our results as a percentage of net sales for the periods indicated:

	For the three months ended September 30,	
	2012	2011
Sales, net	100.0%	100.0%
Costs and expenses:		
Cost of sales	81.5%	74.7%
Selling and administrative	14.1%	19.7%
	<u>95.6%</u>	<u>94.4%</u>
Income from operations	<u>4.4%</u>	<u>5.6%</u>
Other expense, net		
Change in fair value of derivative liabilities	(12.8%)	0.1%
Interest expense	(2.9%)	(2.4%)
Net gain (loss) on disposal of property and equipment	<u>(0.1%)</u>	<u>0.0%</u>
Other expense, net	<u>(15.8%)</u>	<u>(2.3%)</u>
(Loss) income before income taxes	(11.4%)	3.3%
Federal and state income taxes, net	<u>0.0%</u>	<u>0.0%</u>
Net (loss) income	<u>(11.5%)</u>	<u>3.3%</u>

### For the three months ended September 30, 2012 compared to the three months ended September 30, 2011

**Sales, net.** Sales, net, for the three months ended September 30, 2012 and 2011 were \$8.5 million and \$10.9 million, respectively, a decrease of 22%, and are comprised of the following:

	Three months ended September 30,		Dollar	Percentage
	2012	2011	Decrease 2012 vs 2011	Change 2012 vs 2011
	<i>(amounts in thousands)</i>			
Nutraceuticals - U.S. Customers	\$ 5,962	\$ 7,568	\$ (1,606)	(21.2%)
Nutraceuticals - International Customers	2,518	3,308	(790)	(23.9%)
<b>Total</b>	<u>\$ 8,480</u>	<u>\$10,876</u>	<u>\$ (2,396)</u>	<u>(22.0%)</u>

For the three months ended September 30, 2012, approximately 72% of total net sales were derived from two customers as compared to approximately 80% of total net sales from two customers for the three months ended September 30, 2011. The loss of any of these customers could have an adverse affect on our operations.

The decrease in our net sales is primarily the result of the decrease in the volume of sales to (i) one of our significant customers, Costco Wholesale Corporation, in our proprietary branded nutraceutical product line of \$1.6 million, (ii) \$0.5 million to other customers in our branded nutraceutical product line (primarily U.S. customers decrease) and (iii) approximately \$0.4 million in our contract manufacturing product sales primarily due to decreased sales volumes to our major customer, Herbalife of \$1.1 million, offset in part, by increases in sales to a new customer of \$0.7 million.

**Cost of sales.** Cost of sales decreased by \$1.2 million to \$6.9 million for the three months ended September 30, 2012, as compared to \$8.1 million for the three months ended September 30, 2011. Cost of sales increased as a

percentage of sales to 81.5% for the three months ended September 30, 2012 as compared to 74.7% for the three months ended September 30, 2011. The decrease in the cost of goods sold amount was primarily the result of decreased sales. The cost of sales as a percentage of sales increased as a result of a greater percentage of sales being derived from our contract manufacturing, which has a higher cost of goods sold percentage (approximately 84%) as compared to the proprietary branded nutraceutical product line (approximately 57%).

**Selling and Administrative Expenses.** Selling and administrative expenses were \$1.2 million for the three months ended September 30, 2012, as compared to \$2.1 million for the three months ended September 30, 2011, a decrease of approximately \$0.9 million or 44%. As a percentage of sales, net, selling and administrative expenses were 14.1% for the three months ended September 30, 2012 and 19.7% for the prior comparable period.

The net decrease in selling and administrative expenses of \$0.9 million is mainly due to decreases in advertising and other marketing expenses (\$0.6 million) and compensation and employee benefits (\$0.1 million).

Our advertising and marketing costs decreased by approximately \$0.6 million in the three months ended September 30, 2012 compared to the three months ended September 30, 2011 primarily as a result of a decrease in in-store demonstrations (“demos”) of our products at one of our customer’s store locations. As a percentage of sales, our advertising and marketing costs represented 2.5% in the three months ended September 30, 2012 compared to 7.5% in the three months ended September 30, 2011. The decrease in marketing and advertising expenses is a direct result of the decreases in sales of approximately \$2.0 million in our branded proprietary nutraceutical products as well as a move away from performing in-store demos on our products and to instead, offering promotional discounts to consumers to increase our pull through rates.

Our compensation and employee benefits decreased by \$0.1 million as a result of decreasing our staff primarily as a result of closing our warehouse facility in Texas.

**Other expense, net.** Other expense, net was approximately \$1.3 million for the three months ended September 30, 2012 compared to \$0.2 million for the three months ended September 30, 2011, and is composed of:

	Three months ended	
	September 30,	
	2012	2011
	(dollars in thousands)	
Interest expense	\$ (248)	\$ (260)
Other (expense) income:		
Change in fair value of derivative instruments	(1,085)	10
Other, net	(6)	3
Other expense, net	<u>\$ (1,339)</u>	<u>\$ (247)</u>

The change in fair value of derivative liabilities was mainly the result of the increase in the trading price of our common stock from \$0.09 as of June 30, 2012 to \$0.25 as of September 30, 2012. The closing trading price of our stock is one of the variables used to calculate the estimated fair value of our derivative liabilities associated with the underlying derivative instruments.

**Federal and state income tax, net.** For the three months ended September 30, 2012 and 2011, we had a minimal amount of state tax expenses. We continue to maintain a full reserve on our deferred tax assets as it has been determined that based upon past losses, the Company’s past liquidity concerns and the current economic environment, that it is “more likely than not” the Company’s deferred tax assets may not be realized.

**Net (loss) income.** Our net loss for the three months ended September 30, 2012 was \$0.9 million as compared to net income of \$0.4 million for the three months ended September 30, 2011. The change in net (loss) income of

approximately \$1.3 million is primarily the result of the increase in other expense of \$1.0 million and a decrease in income from operations of approximately \$0.2 million.

### ***Seasonality***

The nutraceutical business tends to be seasonal. We have found that in our first fiscal quarter ending on September 30th of each year, orders for our branded proprietary nutraceutical products usually slow (absent the addition of new customers or a new product launch with a significant first time order), as buyers in various markets may have purchased sufficient inventory to carry them through the summer months. Conversely, in our second fiscal quarter, ending on December 31st of each year, orders for our products increase as the demand for our branded nutraceutical products seems to increase in late December to early January as consumers become health conscious as they enter the new year.

The Company believes that there are other non-seasonal factors that also may also influence the variability of quarterly results including, but not limited to, general economic and industry conditions that affect consumer spending, changing consumer demands and current news on nutritional supplements. Accordingly, a comparison of the Company's results of operations from consecutive periods is not necessarily meaningful, and the Company's results of operations for any period are not necessarily indicative of future periods.

### ***Liquidity and Capital Resources***

The following table sets forth, for the periods indicated, the Company's net cash flows used in operating, investing and financing activities, its period end cash and cash equivalents and other operating measures:

	For the three months ended September 30,	
	2012	2011
	<i>(dollars in thousands)</i>	
Net cash (used in) provided by operating activities	\$ (126)	\$ 217
Net cash provided by investing activities	\$ 10	\$ 1
Net cash provided (used in) by financing activities	\$ 187	\$ (12)
Cash at end of period	\$ 216	\$ 931

At September 30, 2012, our working capital deficit was approximately \$3.3 million, a decrease of approximately \$0.2 million in our working capital deficit of approximately \$3.5 million at June 30, 2012. Our current assets increased by \$0.5 million and our current liabilities increased by \$0.3 million.

Net cash used in operating activities of \$0.1 million in the three months ended September 30, 2012, includes net loss of approximately \$1.0 million. After excluding the effects of non-cash expenses, including depreciation and amortization, and changes in the fair value of derivative liabilities, the adjusted cash provided from operations before the effect of the changes in working capital components was \$0.3 million. Cash was used in operations from our working capital assets and liabilities in the amount of approximately \$0.4 million and was the result of increases in accounts receivable and inventories of \$0.2 million each.

Net cash provided by operating activities of \$0.2 million in the three months ended September 30, 2011, includes net income of \$0.4 million. After excluding the effects of non-cash expenses, including depreciation and amortization, compensation expense for employee stock options and consultants and changes in the fair value of derivative liabilities, the adjusted cash provided from operations before the effect of the changes in working capital components was \$0.5 million. Cash was used in operations from our working capital assets and liabilities in the amount of approximately \$0.3 million and was the result of increases in accounts receivable of \$0.7 million

and a decrease in accounts payable and accrued expenses of \$0.6 million, offset by an increase in inventories of approximately \$1.0 million.

Cash provided by investing activities was from the sale of machinery and equipment of \$18,000 and \$2,000, offset by the use of cash for the purchase of fixed assets of approximately \$8,000 and \$1,000 in the three months ended September 30, 2012 and 2011, respectively.

Cash provided by financing activities was approximately \$187,000 for the three months ended September 30, 2012, \$8.5 million from advances under our revolving credit facility offset by payments under our revolving credit facility of \$8.2 million and repayments of principal under our term note in the amount of \$90,000. Cash used in financing activities was approximately \$12,000 for the three months ended September 30, 2011 for payments under our capitalized lease obligation.

As of September 30, 2012, we had cash of \$0.2 million, funds available under our revolving credit facility of approximately \$1.4 million and a working capital deficit of \$3.3 million. Our working capital deficit includes (i) \$3.0 million outstanding under our revolving line of credit which is not due until July 2017 but classified as current due to a subjective acceleration clause that could cause the advances to become currently due and (ii) \$1.0 million in long term debt which is also classified as currently due as a result of a prepayment provision which requires the company to sell its iBio, Inc. common stock if the trading price per share falls below a certain level and use the proceeds to repay our term loan with PNC. (See Note 5 to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q). Furthermore, although we had a loss for the three months ended September 30, 2012, we had income from operations of approximately \$0.4 million in the three months ended September 30, 2012. After taking into consideration our interim results and current projections, management believes that operations, together with the revolving credit facility will support our working capital requirements for the quarter ending September 30, 2013.

Our total annual commitments at September 30, 2012 for long term non-cancelable leases of approximately \$592,000 consists of obligations under operating leases for facilities and operating lease agreements for the rental of warehouse equipment, office equipment and automobiles.

On May 15, 2012, Cedarburg Pharmaceuticals, Inc. ("Cedarburg") sent us a letter (the "Demand Letter") setting forth a demand for indemnification under the Stock Purchase Agreement, dated March 17, 2009 (the "Cedarburg SPA"), by and among Cedarburg, InB: Hauser Pharmaceutical Services, Inc., InB: Paxis Pharmaceuticals, Inc. and the Company. In the Demand Letter, Cedarburg demanded payment by us of \$0.6 million in respect of the Company's indemnification obligations under the Cedarburg SPA. In addition, in the Demand Letter, Cedarburg informed us that there are also environmental issues pending which may lead to additional costs to Cedarburg which will likely be in excess of \$0.3 million.

On May 30, 2012, we sent a letter responding to the Demand Letter and setting forth our position that we have no obligation to indemnify Cedarburg as demanded. On June 18, 2012, Cedarburg responded to our letter and, on July 27, 2012, we sent another letter to Cedarburg reiterating our position that it has no obligation to indemnify Cedarburg as demanded. As of November 19, 2012, we have not received any further communication from Cedarburg with respect to its demand for indemnification as set forth in the Demand Letter. We intend to vigorously contest Cedarburg's demand as set forth in the Demand Letter.

### ***Capital Expenditures***

The Company's capital expenditures for the three months ended September 30, 2012 and 2011 were approximately \$8,000 and \$1,000, respectively. The Company has budgeted approximately \$0.5 million for capital expenditures for fiscal 2013. The total amount is expected to be funded from cash provided from its operations and from lease financing.

### ***Off-Balance Sheet Arrangements***

The Company has no off-balance sheet arrangements.

### ***Recent Accounting Pronouncement***

None.

### ***Impact of Inflation***

The Company does not believe that inflation has significantly affected its results of operations.

## **Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Not applicable.

## **Item 4. CONTROLS AND PROCEDURES**

### **Disclosure Controls and Procedures**

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed by the Company in the reports it files or submits under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) is recorded, processed, summarized, and reported within the time periods specified by the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Under the supervision and with the participation of management, including the Chief Executive Officer and Chief Financial Officer, the Company has evaluated the effectiveness of its disclosure controls and procedures (as such term is defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2012, and, based upon this evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that these controls and procedures are effective in providing reasonable assurance of compliance.

### **Changes in Internal Control over Financial Reporting**

No change in our internal control over financial reporting occurred during the three months ended September 30, 2012 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## PART II – OTHER INFORMATION

### Item 1. LEGAL PROCEEDINGS

None.

### Item 1A. Risk Factors

The risks described in Item 1A, Risk Factors, in our Annual Report on Form 10-K for the year ended June 30, 2012, could materially and adversely affect our business, financial condition and results of operations. The risk factors discussed in that Form 10-K do not identify all risks that we face because our business operations could also be affected by additional factors that are not presently known to us or that we currently consider to be immaterial to our operations. There have been no material changes to our risk factors from those disclosed in our Form 10-K for the year ended June 30, 2012.

### Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

### Item 3. DEFAULTS UPON SENIOR SECURITIES

None.

### Item 4. MINE SAFETY DISCLOSURE

Not Applicable.

### Item 5. OTHER INFORMATION

None.

### Item 6. EXHIBITS

#### (a) Exhibits

#### **Exhibit Number**

- |      |   |
|------|---|
| 31.1 | Certification of pursuant to Section 302 of Section 302 of the Sarbanes-Oxley Act of 2002 by Chief Executive Officer.   |
| 31.2 | Certification of pursuant to Section 302 of Section 302 of the Sarbanes-Oxley Act of 2002 by Chief Financial Officer.   |
| 32.1 | Certification of periodic financial report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 by Chief Executive Officer.  |
| 32.2 | Certification of periodic financial report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 by Chief Financial Officer.  |
| 101  | The following financial information from Integrated Biopharma, Inc.'s Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Statements of Operations for the three months ended September 30, 2012 and 2011, (ii) Condensed Consolidated Balance Sheets as of September 30, 2012 and June 30, 2012, (iii) Condensed Consolidated Statements of Cash Flows for the three months ended September 30, 2012 and 2011, and (iv) the Notes to Condensed Consolidated Statements. |

## SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

### INTEGRATED BIOPHARMA, INC.

Date: November 19, 2012

By: /s/ E Gerald Kay  
E, Gerald Kay,  
President and Chief Executive Officer

Date: November 19, 2012

By: /s/ Dina L. Masi  
Dina L. Masi,  
Chief Financial Officer & Senior Vice President

**Certification of Chief Executive Officer**

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, E. Gerald Kay certify that:

1. I have reviewed this quarterly report on Form 10-Q of Integrated BioPharma, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 19, 2012

By: /s/ E. Gerald Kay

Name: E. Gerald Kay

Title: President and Chief Executive Officer



**Certification of Chief Financial Officer**

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Dina L. Masi, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Integrated BioPharma, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 19, 2012

By: /s/ Dina L. Masi

Name: Dina L. Masi

Title: Chief Financial Officer &amp; Senior Vice President

**CERTIFICATION OF PERIODIC REPORT**

As adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q for the first quarter ended September 30, 2012 of Integrated BioPharma, Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), E. Gerald Kay, the President and Chief Executive Officer of Integrated BioPharma, Inc. certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to his knowledge:

- (1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
- (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This certification accompanies the Report pursuant to Section 906 of Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Dated: November 19, 2012

By: /s/ E. Gerald Kay  
E. Gerald Kay  
President and Chief Executive Officer

**CERTIFICATION OF PERIODIC REPORT**

As adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q for the first quarter ended September 30, 2012 of Integrated BioPharma, Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Dina L. Masi, the Senior Vice President and Chief Financial Officer of Integrated BioPharma, Inc. certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to her knowledge:

- (1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
- (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This certification accompanies the Report pursuant to Section 906 of Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Dated: November 19, 2012

By: /s/ Dina L. Masi  
Dina L. Masi  
Chief Financial Officer & Senior Vice President